Skip to main content

Advertisement

Table 1 Clinical characteristics of the neo-adjuvant cohort

From: Dual roles for immune metagenes in breast cancer prognosis and therapy prediction

Characteristic MDACC-701  
  Number Percentage
Age at diagnosis, years   
 40 134 19
 41-50 247 35
 >50 320 46
Chemotherapy type   
 FAC 74 11
 FAC + paclitaxel 236 34
 FAC + docetaxel 61 9
 FEC 33 5
 FEC + paclitaxel 73 10
 Paclitaxel 65 9
 Docetaxel 39 6
 Unspecified 120 17
Chemotherapy response   
 pCR or RCB 0,1 188 27
 No pCR or RCB 2,3 492 70
 Unspecified 21 3
Estrogen receptor status   
 Positive 385 55
 Negative 300 43
 Unspecified 16 2
HER2/neu status   
 Positive 65 9
 Negative 561 80
 Unspecified 75 11
Intrinsic subtypes   
 Basal 211 30
 LumA 216 31
 LumB 135 19
 HER2-E 74 11
 Claudin-low 47 7
 Normal-like 16 2
 Unspecified 2 0.3
  1. FAC = cyclophosphamide, doxorubicin, 5-FU; FEC =5-FU, epirubicin, cyclophosphamide; HER2-E, HER2-enriched; LumA = luminal A; LumB = luminal B; pCR = complete pathologic response; RCB = residual cancer burden.